THE WOODLANDS, Texas
July 10, 2012
/PRNewswire/ -- Pernix Therapeutics (NYSE: MKT: PTX), a specialty pharmaceutical company, today announced that
is now available to patients for the treatment of
) infection and duodenal ulcer disease (active or one-year history) to eradicate
in adult patients.
is a ten-day, triple combination oral therapy comprised of omeprazole delayed-release capsules (20 mg), clarithromycin tablets (500 mg) and amoxicillin capsules (500 mg).
, President and Chief Executive Officer of Pernix, said, "We are pleased to announce that
is now available by prescription in pharmacies across the country, and physicians and patients will have another therapy option for the treatment of
duodenal ulcer disease."
is the first triple combination medication indicated to eradicate symptoms of
in just ten days. Current treatment options include dual therapy, consisting of one proton pump inhibitor and only one antibiotic medication, as well as triple combination therapy, prescribed twice daily for 14 days.
, M.D., Professor of Medicine, Division of Gastroenterology at Oregon Health & Science University, said, "Published studies show that a single ten-day regimen of twice-daily therapy with omeprazole, amoxicillin and clarithromycin eradicates 80 percent to 90 percent of
Omeprazole is an antisecretory drug, which works by decreasing the amount of acid the stomach produces. Clarithromycin and amoxicillin are antibacterial drugs, which inhibit the growth of bacteria allowing the stomach lining to heal. Omeclamox-Pak is contraindicated in patients with a history of hypersensitivity to omeprazole, any macrolide antibiotic or penicillin. The safety and effectiveness of Omeclamox-Pak in the pediatric population has not yet been established. Omeclamox-Pak was approved by the U.S. Food and Drug Administration in 2011.
Full prescribing information is available at